- Home
- WYY vs MAIA Comparison
WYY vs MAIA Comparison
Compare WYY & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WYY
- MAIA
- Stock Information
- Founded
- WYY 1991
- MAIA 2018
- Country
- WYY United States
- MAIA United States
- Employees
- WYY N/A
- MAIA N/A
- Industry
- WYY EDP Services
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- WYY Technology
- MAIA Health Care
- Exchange
- WYY Nasdaq
- MAIA Nasdaq
- Market Cap
- WYY 48.9M
- MAIA 44.9M
- IPO Year
- WYY 1998
- MAIA 2022
- Fundamental
- Price
- WYY $6.72
- MAIA $1.12
- Analyst Decision
- WYY Strong Buy
- MAIA
- Analyst Count
- WYY 3
- MAIA 0
- Target Price
- WYY $8.67
- MAIA N/A
- AVG Volume (30 Days)
- WYY 51.2K
- MAIA 218.7K
- Earning Date
- WYY 11-13-2025
- MAIA 11-07-2025
- Dividend Yield
- WYY N/A
- MAIA N/A
- EPS Growth
- WYY N/A
- MAIA N/A
- EPS
- WYY N/A
- MAIA N/A
- Revenue
- WYY $145,926,414.00
- MAIA N/A
- Revenue This Year
- WYY $9.07
- MAIA N/A
- Revenue Next Year
- WYY $13.20
- MAIA N/A
- P/E Ratio
- WYY N/A
- MAIA N/A
- Revenue Growth
- WYY 9.62
- MAIA N/A
- 52 Week Low
- WYY $2.19
- MAIA $0.87
- 52 Week High
- WYY $7.55
- MAIA $2.74
- Technical
- Relative Strength Index (RSI)
- WYY 55.06
- MAIA 49.13
- Support Level
- WYY $6.17
- MAIA $0.87
- Resistance Level
- WYY $6.85
- MAIA $1.09
- Average True Range (ATR)
- WYY 0.43
- MAIA 0.08
- MACD
- WYY -0.03
- MAIA 0.02
- Stochastic Oscillator
- WYY 70.50
- MAIA 86.21
About WYY WidePoint Corporation
WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and an Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically, the company generates a majority of its revenue from the United States and the rest from Europe.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.